TriangleCD123-CAR T (NCT04318678)
CD123-CAR T trial for AML/MDS (NCT04318678). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
Acute myeloid leukemia in children is harder to treat than the common childhood leukemia; when it returns after transplant, options are few.
The idea: a CAR T cell for AML, built at the hospital that treats these children most.
The cells target CD123, a receptor found on AML cells, on the leukemia stem cells that seed relapse, and on several rarer leukemias. T cells from the child, or their prior transplant donor, are fitted with the receptor and infused once after chemotherapy clears space.
The first question is safety, since CD123 also sits on some normal blood-forming cells.
CATCHAML runs at St. Jude in Memphis, for patients up to twenty-one, led by Swati Naik and Paulina Velasquez. Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.